Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

LENVIMA, KEYTRUDA Receive Breakthrough Therapy Designation as Combo Therapy for RCC

By Merck | January 9, 2018

A sign at the entrance to a Merck plant in Rahway, New Jersey on July 17, 2017.

Eisai Co., Ltd. and Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that they received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for Eisai’s multiple receptor tyrosine kinase inhibitor LENVIMA (lenvatinib) in combination with Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) for the potential treatment of patients with advanced and/or metastatic renal cell carcinoma (RCC). The LENVIMA and KEYTRUDA combination therapy is being jointly developed by Eisai and Merck. This is the second Breakthrough Therapy Designation for LENVIMA and the twelfth Breakthrough Therapy Designation granted to KEYTRUDA.

The Breakthrough Therapy Designation is an FDA program intended to expedite development and review of drugs for serious or life-threatening conditions. In order to qualify for this designation, preliminary clinical evidence must demonstrate that the drug may provide substantial improvement over currently available therapy on at least one clinically significant endpoint. The benefits of this Breakthrough Therapy Designation include more intensive guidance on an efficient drug development program, access to a regulatory liaison to help accelerate review time and eligibility for rolling review as well as priority review.

This Breakthrough Therapy Designation was based on the results of the RCC cohort in Study 111, a multicenter, open-label phase 1b/2 clinical study being carried out in the U.S. and the European Union (EU) to evaluate the efficacy and safety of LENVIMA in combination with KEYTRUDA in subjects with selected solid tumors.

Dr. Takashi Owa, vice president, chief medicine creation officer, oncology business group, Eisai, commented: “We are encouraged that the FDA has recognized the potential of LENVIMA plus KEYTRUDA for patients with advanced and/or metastatic renal cell carcinoma with the Breakthrough Therapy Designation. As a human health care company dedicated to giving our first thought to patients, we are committed to working closely with Merck and the FDA to expedite this clinical program with the hope that we may offer another important option for patients in need.”

“The FDA’s Breakthrough Therapy Designation for the LENVIMA and KEYTRUDA combination in advanced and/or metastatic renal cell carcinoma provides us with the opportunity to accelerate our effort to bring an important potential treatment option to these patients,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. “We remain committed to understanding the full potential of KEYTRUDA across cancers and treatment settings, and our collaboration with Eisai is one of the many ways we are executing on this commitment to helping more patients.”

The combination of LENVIMA (lenvatinib) and KEYTRUDA (pembrolizumab) is investigational. The efficacy and safety of this combination has not been established.

About Study 111

Study 111 is a multicenter, open-label phase 1b/2 clinical study being carried out in the U.S. and EU to evaluate the efficacy and safety of LENVIMA in combination with KEYTRUDA. The primary objective of the phase 1b part was to determine the maximum tolerated dose. Patients with unresectable solid tumors (renal cell carcinoma, endometrial cancer, non-small cell lung cancer, urothelial cancer, squamous cell head and neck cancer and melanoma) who had progressed after treatment with approved therapies or for which there are no standard effective therapies available were administered 24 mg of LENVIMA orally daily, as well as 200 mg of KEYTRUDA intravenously every three weeks. Dose reductions of LENVIMA were permitted based on observed toxicity. The phase 2 part was conducted with patients who had select solid tumors with 0-2 prior lines of systemic therapy (unless discussed with the sponsor), with a recommended dosage of 20 mg of LENVIMA daily and 200 mg of KEYTRUDA every three weeks as determined based on the results of the phase 1b part. The primary endpoint of the phase 2 part was objective response rate at 24 weeks after treatment began, with select secondary endpoints including objective response rate, disease control rate, progression-free survival and duration of response. Currently, the phase 2 part is underway, with enrollment expanded for the endometrial cancer cohort.


Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE